Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limited-term orelabrutinib-based OBR/OR treatment for previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
ChiCTR2400085707Phase 2Recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, bendamustine and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Shanxi Provincial People's Hospital. Primary endpoint: Objective response rate. Started Jun 2024; status: recruiting.
02
Drugs
orelabrutinibbendamustinerituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2400085707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085707.